Ibrexafungerp Production Cost Reports

The report provides a detailed analysis essential for establishing an Ibrexafungerp production plant. It encompasses all critical aspects necessary for Ibrexafungerp production, including the cost of Ibrexafungerp production, Ibrexafungerp plant cost, Ibrexafungerp production costs, and the overall Ibrexafungerp production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Ibrexafungerp production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ibrexafungerp is an antifungal drug used mainly in the treatment of fungal infections caused by Candida species. It is especially used for managing vulvovaginal candidiasis, including cases where infections are recurrent or resistant to commonly used azole antifungal medicines. It works by targeting the fungal cell wall, which helps stop fungal growth and leads to the elimination of the infection. It is mainly utilised in the treatment of vaginal yeast infections in adult and pediatric females who have experienced their first menstrual period. It is often used in invasive fungal infections in hospitalised patients. It is also being studied for its potential use in treating other serious fungal infections, particularly in patients with weakened immune systems.

The demand for Ibrexafungerp is primarily driven by its application as an antifungal agent to treat vulvovaginal candidiasis (VVC) in adult and post-menarchal pediatric females, which supports its market growth. Its application as a novel antifungal medication in the treatment as well as prevention of recurrent episodes of vulvovaginal candidiasis further promotes its demand in the pharmaceutical industry.

Its demand as an antifungal agent for the treatment of invasive and resistant fungal infections also boosts its market growth. Its demand as a reference drug in the medical research and biotechnology industries for addressing antifungal resistance and expanding treatment options in clinical practice also contributes to its market expansion. Several factors, including the cost and availability of raw materials, regulatory compliance, and adherence to environmental standards, greatly influence Industrial Ibrexafungerp procurement. Furthermore, advancements in production technologies, reliability of suppliers, sustainable production practices, and streamlined logistics also play an important role in shaping global market trends for Ibrexafungerp procurement.

Raw Material for Ibrexafungerp Production

According to the Ibrexafungerp production plant project report, the major raw materials for Ibrexafungerp production includes Enfumafungin.

Production Process of Ibrexafungerp

The extensive Ibrexafungerp production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Ibrexafungerp begins with Enfumafungin, where its lactone ring is reduced to form a pyran structure. Further, the removal of the sugar unit through acid-mediated hydrolysis produces a major intermediate. Then, this intermediate is converted into a benzyl ester, which allows further modification through coupling with a chiral sulfonyl azepane fragment to form an ether linkage. The molecule is subsequently subjected to a metal reduction step that also removes the sulfonyl protecting group, which forms a simplified core structure. Then, this core is transformed into a hydrazine intermediate, which undergoes a final cyclocondensation reaction with an amide derivative under acidic conditions to give Ibrexafungerp as the final product.

Ibrexafungerp is a first-in-class triterpenoid antifungal agent that acts as a glucan synthase inhibitor. It appears as a white to off-white solid and is administered orally for the treatment of vulvovaginal candidiasis. The molecular formula of the free base compound is C44H67N5O4, and its molecular mass is 730.05 g/mol. The compound is orally bioavailable and reaches peak plasma concentrations within 4 to 6 hours after oral administration. It has a half-life of approximately 20 hours, which allows for convenient dosing regimens. The boiling point of the compound is around 815.9 degree Celsius, and its density is around 1.22 gm/cm3. Ibrexafungerp demonstrates concentration-dependent fungicidal activity against Candida species and fungistatic activity against Aspergillus species, with notable efficacy against multidrug-resistant fungal pathogens, including azole-resistant and echinocandin-resistant strains.